Trazodone may have a secondary low-dose mechanism through astrocyte and microglial inflammatory modulation, potentially shifting GFAP, IL-6, YKL-40, or kynurenine-pathway markers. This is the weakest surviving biological mechanism worth embedding in a trial as a secondary pharmacodynamic package, not as a lead disease-modifying hypothesis.
No AI visual card yet
No linked debates yet. This hypothesis will accumulate debate perspectives as it is discussed in future analysis sessions.
No clinical trials data available
Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.
High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.
Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.
Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.
No knowledge graph edges recorded
No comments yet. Be the first to comment!